The primary end point of the trial was the rate of death at 28 days. Secondary end points were the rates of death in the ICU, in the hospital, at 6 months, and at 12 months; the duration of stay in the ICU; the number of days without need for organ support (i.e., vasopressors, ventilators, or renal-replacement therapy); the time to attainment of hemodynamic stability (i.e., time to reach a mean arterial pressure of 65 mm Hg)16; the changes in hemodynamic variables; and the use of dobutamine or other inotropic agents. Adverse events were categorized as arrhythmias (i.e., ventricular tachycardia, ventricular fibrillation, or atrial fibrillation), myocardial necrosis, skin necrosis, ischemia in limbs or distal extremities, or secondary infections.17

The simplest method to measure an athlete's vertical jump is to get the athlete to reach up against a flat wall, with a flat surface under his/her feet (such as a gym floor or concrete) and record the highest point he/she can reach flat-footed (the height of this point from the ground is referred to as "standing reach"); fingertips powdered with chalk can facilitate the determination of points touched on the wall. The athlete then makes an effort to jump up with the goal of touching the highest point on the wall that he or she can reach; the athlete can perform these jumps as many times as needed. The height of the highest point the athlete touches is recorded. The difference between this height and the standing reach is the athlete's vertical jump.